A novel small-molecule inverse agonist, HEP-50768, effectively targets MRGPRX4 and suppresses cholestatic itch in preclinical models.
- 1 cites
Moving in bioRxiv, Nature Chemical Biology.
Rebuilt
Nothing in this area has moved yet this week.
Newest first · last 60 days
A novel small-molecule inverse agonist, HEP-50768, effectively targets MRGPRX4 and suppresses cholestatic itch in preclinical models.
Journals this month
Moving areas, week to 3 Oct 2026